Morphogen-induced dendritic growth
View Patent ↗Disclosed are methods and compositions for maintaining neural pathways in a mammal including: enhancing survival of neurons at risk of dying; inducing cellular repair of damaged neurons and neural pathways; stimulating neurons to maintain their differentiated phenotype; and promoting dendritic outgrowth, including maintaining dendritic arbors and regenerating dendritic architecture. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration. In another embodiment, the invention provides methods and compositions which include a morphogen or morphogen-stimulating agent, and a nerve trophic factor or nerve trophic factor-stimulating agent at concentrations effective for stimulating dendrite outgrowth. The morphogen and the nerve trophic factor can be admixed in combination.
1. A method for promoting dendrite outgrowth by a neuron, comprising contacting said neuron with a composition comprising a morphogen, wherein said morphogen comprises a dimeric protein having an amino acid sequence selected from:
(1) a conserved C-terminal seven-cysteine skeleton at least about 60% identical or 70% homologous to the residues 38-139 of SEQ ID NO: 5;
(2) generic sequence 3 (SEQ ID NO: 3) or generic sequence 4 (SEQ ID NO: 4);
(3) generic sequence 5 (SEQ ID NO: 30) or generic sequence 6 (SEQ ID NO: 31); or
(4) generic sequence OPX (SEQ ID NO: 29);
wherein said morphogen promotes dendrite outgrowth in said neuron.
2. The method of claim 1 , wherein said morphogen comprises residues 38-139 of SEQ ID NO: 5.
3. The method of claim 1 , wherein said morphogen comprises the amino acid sequence of SEQ ID NO: 5.
4. The method of claim 1 , wherein said morphogen comprises residues 38-139 of SEQ ID NO: 6.
5. The method of claim 1 , wherein said morphogen comprises the amino acid sequence of SEQ ID NO: 6.
6. The method of claim 1 , wherein said morphogen is a CBMP2 polypeptide.
7. The method of claim 6 , wherein said CBMP2 polypeptide comprises the amino acid sequence of SEQ ID NO: 9.
8. The method of claim 6 , wherein said CBMP2 polypeptide comprises the amino acid sequence of SEQ ID NO: 10.
9. The method of claim 1 , wherein said morphogen is a BMP-6 polypeptide.
10. The method of claim 9 , wherein said BMP-6 polypeptide comprises the amino acid sequence of SEQ ID NO: 28.
11. The method of claim 1 , wherein said morphogen is a 60A polypeptide.
12. The method of claim 11 , wherein said 60A polypeptide comprises the amino acid sequence of SEQ ID NO: 24.
13. The method of claim 1 , wherein the composition includes NGF.
14. The method of claim 1 , wherein the neurons are sympathetic neurons.
15. The method of claim 1 , wherein said morphogen is human OP-1, mouse OP-1, human OP-2, mouse OP-2, BMP5, BMP6, Vgr-1, 60A, BMP2A, BMP-2B, DPP, Vgl, GDF-1, or BMP3.
16. The method of claim 1 , wherein said morphogen is human OP-1, mouse OP-1, human OP-2, mouse OP-2, BMP5, BMP6, Vgr-1, 60A, BMP2A, BMP-2B, DPP, Vgl, or GDF-1.
17. The method of claim 1 , wherein said morphogen is human OP-1, mouse OP-1, human OP-2, mouse OP-2, BMP5, BMP6, Vgr-1, 60A, BMP2A, BMP-2B, or DPP.
18. The method of claim 1 , wherein said morphogen is human OP-1, mouse OP-1, human OP-2, mouse OP-2, BMP5, BMP6, Vgr- 1, 60A, BMP2A, or BMP-2B.